Daily Suraj

English

India's Indigenous Bird Flu Vaccine to Cost Just Rs 1–2 Per Dose, Offer Six-Month Protection

21 Nov, 2026 02:20 PM

India has achieved a major breakthrough in the fight against bird flu with the launch of its first indigenously developed H5N1 vaccine. Developed by scientists in Bhopal, the vaccine is expected to help protect the poultry sector from heavy financial losses caused by bird flu outbreaks and reduce the risks associated with the spread of the disease.
 

Scientists at the National Institute of High Security Animal Diseases (NIHSAD), Anand Nagar, Bhopal, under the Indian Council of Agricultural Research (ICAR), developed the vaccine against Clade 2.3.2.1a of the avian influenza virus.
 

Union Agriculture and Farmers Welfare Minister Shivraj Singh Chouhan formally launched the vaccine on Friday. Praising the scientists for their achievement, he also announced the construction of a BSL-4 laboratory at the institute at an estimated cost of Rs 300 crore.
 

The vaccine is expected to provide protection to chickens for approximately six months. One of its key features is its affordability, with the estimated cost of a single dose ranging between Rs 1 and Rs 2.
 

Vaccine Developed in Just 11 Months
 

The development process began in September 2025 and was completed in August 2026. The research was carried out by a team of experts under the leadership of NIHSAD Director Dr Aniket Sanyal, with scientist Dr S. Nagarajan leading the research work.
 

The vaccine was also tested at the institute. During the trial, a vaccinated chicken was exposed to the bird flu virus. The infection did not spread to another chicken kept in the same infected environment, indicating the vaccine's potential to help prevent disease transmission.
 

The vaccine is expected to be particularly beneficial for egg-laying hens and breeding birds. Its use in poultry farms could help reduce the risk of infection spreading among birds and limit the transmission of the virus.
 

Potential Demand of Up to 100 Crore Doses Annually
 

Considering India's poultry population of approximately 851.8 million chickens, the vaccine has significant potential for large-scale use.
 

According to the institute, the estimated cost of each dose will be between Rs 1 and Rs 2. Annual demand for the vaccine could reach 80 crore to 100 crore doses.
 

Until now, India did not have a specific commercially available vaccine against this virus. During bird flu outbreaks, large numbers of infected chickens have to be culled in affected areas, resulting in substantial financial losses for poultry farmers and businesses.
 

The introduction of the indigenous vaccine could help reduce these losses by strengthening disease prevention and control measures in the poultry sector.
 

ICAR Calls It an Important Step Towards 'One Health'
 

ICAR Director General Dr M.L. Jat described the development as an important step towards the 'One Health' approach. He said India had witnessed more than 500 H5N1 outbreaks since 2006.
 

He emphasised that controlling infections among birds could also help reduce the risk of zoonotic diseases spreading to humans.
 

During the launch, Chouhan highlighted the importance of the poultry sector for rural livelihoods. He said more than 90 lakh small, medium-sized and backyard poultry farmers were engaged in the business across the country.
 

According to the minister, bird flu outbreaks, chicken deaths and large-scale culling severely affect the livelihoods of these families. An indigenous vaccine could play an important role in minimising such economic damage.
 

Chouhan also praised the dedication of the scientists involved in developing the vaccine, describing India's first fully indigenous H5N1 vaccine as evidence of the country's scientific capabilities and commitment to self-reliance.
 

He said the research team had worked day and night for several months without taking leave, demonstrating dedication similar to that of soldiers serving the nation.
 

At the launch event, eight scientists who contributed to the development of the vaccine were honoured with certificates in recognition of their work.

Latest News